mannkind

Q3 2026
Performance Summary

Q3 Total Revenue	Commercial Q3 Sales	Tyvaso DPI® Royalties
+24% YoY	+102% YoY	+16% QoQ
$101.9M	**$45.0M**	**$37.5M**

Momentum Across All 3 Growth Drivers

GROWING
Commercial Products

>100%
growth in commercial product revenue Q3 2026 vs. Q3 2025

Furoscix ReadyFlow™
~75% of shipments converted; >50% growth post-ReadyFlow launch

Afrezza® pediatrics
>2x adult share of mealtime insulin

EXPANDING
UT Collaboration

>$1B
estimated UTHR-related revenues[1], 2027–2030

Tyvaso DPI
+16% QoQ royalty growth

Sole-source manufacturer
Stable manufacturing revenue for years to come

UPSIDE
DPI Platform

3
paths into IPF

Nintedanib DPI
Clean Phase 1b; INFLO-2 streamlined for a faster readout

Out-licensed programs
Tyvaso DPI and ralinepag DPI add potential upside in IPF, PPF & ILD

Three Paths into IPF and Beyond
A differentiated DPI portfolio spanning wholly owned and out-licensed programs

UT Partnership
Tyvaso DPI



Approved in PAH and PH-ILD, with a **potential expansion** opportunity in IPF / PPF

Blockbuster Product

MNKD Owned
Nintedanib DPI



Proven molecule, now paired with **demonstrated tolerability** in IPF

Phase 2 Underway

UT Collaboration
Ralinepag DPI



Next-generation prostacyclin with multi-indication potential

Progressing to IND

NEAR TERM → **MID TERM** → **LONG TERM**

NASDAQ
MNKD

To learn more, visit us at:
investors.mannkindcorp.com

MNKD Investor Relations:
IR@mnkd.com

© Copyright 2026. All rights reserved. MannKind Corporation.

[1] Estimated cumulative MannKind revenues from the United Therapeutics collaboration for 2027–2030; based on current assumptions and not intended as financial guidance.